The Blood Test Revolution: It’s A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor’s Business Daily)

Biotech leaders Guardant Health, Natera, and Exact Sciences are driving a major shift in cancer care through minimal residual disease (MRD) blood tests, which detect trace tumor DNA months before imaging can. These ultrasensitive tests not only identify relapse earlier but also help personalize post-surgical treatment and avoid unnecessary chemotherapy. With a projected market size of $6.7B by 2030, MRD testing is reshaping surveillance, particularly for colorectal, breast, and lung cancers. Though adoption faces hurdles—such as profitability and tissue access—this tech is set to redefine how oncology tracks and treats residual disease.